Withdrawals due to adverse outcomes · Participants with active Crohn's disease despite current treatment with infliximab
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in withdrawal due to adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).
1 finding from 1 review
Serious adverse events up to week 10 · Participants with active Crohn's disease despite current treatment with infliximab
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in serious adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).
1 finding from 1 review
Adverse events up to week 12 · Patients with active Crohn's disease
One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in adverse events up to week 12 compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in withdrawal due to adverse events up to week 12 compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events up to week 12 · Patients with active Crohn's disease
One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).
1 finding from 1 review
Failure to induce remission at 6 weeks · Patients with active Crohn's disease
Two infusions of natalizumab (300 mg or 3 mg/kg) leads to lower failure to induce remission at 6 weeks compared with placebo (high certainty).
2 findings from 1 review
Clinically important upper GI bleeding · people admitted to intensive care units
Interventions probably leads to lower clinically important upper GI bleeding compared with placebo or no prophylaxis (moderate certainty).
1 finding from 1 review
Duration of ICU stay · people admitted to intensive care units
1 finding from 1 review
Blood transfusion · people admitted to intensive care units
H2 receptor antagonists probably leads to lower number of participants requiring blood transfusions compared with placebo or no prophylaxis (moderate certainty).
1 finding from 1 review
Serious adverse events · people admitted to intensive care units
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically important upper GI bleeding · people admitted to intensive care units
Proton pump inhibitors showed no clear difference in clinically important upper GI bleeding compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
Nosocomial pneumonia · people admitted to intensive care units
Proton pump inhibitors showed no clear difference in nosocomial pneumonia compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
ICU mortality · people admitted to intensive care units
Proton pump inhibitors showed no clear difference in all‐cause mortality in ICU compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
Duration of ICU stay · people admitted to intensive care units
1 finding from 1 review
Blood transfusion · people admitted to intensive care units
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people admitted to intensive care units
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically important upper GI bleeding · people admitted to intensive care units
Antacids may leads to lower clinically important upper GI bleeding compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
Nosocomial pneumonia · people admitted to intensive care units
Interventions showed no clear difference in nosocomial pneumonia compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
Nosocomial pneumonia · people admitted to intensive care units
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
ICU mortality · people admitted to intensive care units
Antacids showed no clear difference in all‐cause mortality in ICU compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review